Skip to Content

Xeomin Dosage

Generic name: Botulinum Toxin Type A 50[USP'U]
Dosage form: powder, lyophilized, for solution

Medically reviewed by Last updated on Jul 13, 2018.

Instructions for Safe Use

The potency Units of XEOMIN (incobotulinumtoxinA) for injection are specific to the preparation and assay method utilized. They are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of XEOMIN cannot be compared to or converted into Units of any other botulinum toxin products assessed with any other specific assay method [see Warnings and Precautions (5.2) and Description (11)]. Reconstituted Xeomin is intended for intramuscular or intra-salivary gland injection only.

The recommended maximum cumulative dose for any indication should not exceed 400 Units in a treatment session.

Chronic Sialorrhea

XEOMIN is injected into the parotid and submandibular glands on both sides (i.e., 4 injection sites per treatment session). The recommended total dose per treatment session is 100 Units. The dose is divided with a ratio of 3:2 between the parotid and submandibular glands (Table 1).

Figure 1: Glands for Injection in Chronic Sialorrhea

Figure 1

M = Masseter

Use the following guidelines if locating salivary glands using anatomic landmarks:

To inject the parotid gland, find the midpoint on the line connecting the tragus and mandible angle (Site A and B, respectively, Figure 1), approximately at the height of the ear lobe. Deliver the injection one finger breadth anterior to this site (Star 1, Figure 1).
To inject the submandibular gland, find the midpoint between the angle of the mandible and the tip of the chin (Site B and C, respectively, Figure 1). Deliver the injection one finger breadth medial to the inferior surface of the mandible at this site (Star 2, Figure 1).
Table 1: Dosing by Gland for Treatment of Chronic Sialorrhea
Gland(s) Units Per Side Total
Parotid gland(s) 30 Units 60 Units
Submandibular gland(s) 20 Units 40 Units
Both Glands 50 Units 100 Units

The concentration used in the clinical study after reconstitution is 5 Units/0.1mL. The timing for repeat treatment should be determined based on the actual clinical need of the individual patient, and no sooner than every 16 weeks.

Upper Limb Spasticity

The dosage, frequency, and number of injection sites should be tailored to the individual patient based on the size, number, and location of muscles to be treated, severity of spasticity, presence of local muscle weakness, patient's response to previous treatment, and adverse event history with XEOMIN. The frequency of XEOMIN treatments should be no sooner than every 12 weeks. In spasticity patients not previously treated with botulinum toxins, initial dosing should begin at the low end of the recommended dosing range and titrated as clinically necessary. Most patients in clinical studies were retreated between 12-14 weeks.

Table 2: XEOMIN Dosing by Muscle for Treatment of Upper Limb Spasticity
Clinical Pattern
Units (Range) Number of injection sites per muscle
Clenched Fist
Flexor digitorum superficialis 25 Units-100 Units 2
Flexor digitorum profundus 25 Units-100 Units 2
Flexed Wrist
Flexor carpi radialis 25 Units-100 Units 1-2
Flexor carpi ulnaris 20 Units-100 Units 1-2
Flexed Elbow
Brachioradialis 25 Units-100 Units 1-3
Biceps 50 Units-200 Units 1-4
Brachialis 25 Units-100 Units 1-2
Pronated Forearm
Pronator quadratus 10 Units-50 Units 1
Pronator teres 25 Units-75 Units 1-2
Flexor pollicis longus 10 Units-50 Units 1
Adductor pollicis 5 Units-30 Units 1
Flexor pollicis brevis/Opponens pollicis 5 Units-30 Units 1

Figure 2: Muscles Involved In Adult Upper Limb Spasticity

Figure 2

Cervical Dystonia

The recommended initial total dose of XEOMIN for cervical dystonia is 120 Units. In a placebo-controlled trial utilizing initial XEOMIN doses of 120 Units and 240 Units, no meaningful difference in effectiveness was demonstrated between the doses [see Clinical Studies (14.3)]. In previously treated patients, their past dose, response to treatment, duration of effect, and adverse event history should be taken into consideration when determining the XEOMIN dose.

In the treatment of cervical dystonia, XEOMIN is usually injected into the sternocleidomastoid, levator scapulae, splenius capitis, scalenus, and/or the trapezius muscle(s). This list is not exhaustive, as any of the muscles responsible for controlling head position may require treatment [see Clinical Studies (14.3)]. The dose and number of injection sites in each treated muscle should be individualized based on the number and location of the muscle(s) to be treated, the degree of spasticity/dystonia, muscle mass, body weight, and response to any previous botulinum toxin injections.

The frequency of XEOMIN repeat treatments should be determined by clinical response, but should generally be no more frequent than every 12 weeks [see Clinical Studies (14.3)].


The recommended initial total dose of XEOMIN should be the same dose as the patient's previous treatment of onabotulinumtoxinA (Botox), although responses to XEOMIN and onabotulinumtoxinA (Botox) may differ in individual patients. In a placebo-controlled trial in which patients were dosed with the same number of Units as they had received previously with onabotulinumtoxinA (Botox), the mean dose per eye was about 33 Units (range 10 Units-50 Units), and the mean number of injections per eye was 6. The maximum dose per eye in the controlled trials was 50 Units, with a range of 10 Units-50 Units. In the controlled trial, few patients received a total dose of greater than 75 Units.

If the previous dose of Botox is not known, the initial dose of XEOMIN should be between 1.25 Units-2.5 Units/injection site.

The total initial dose of XEOMIN in both eyes should not exceed 70 Units (35 Units/eye).

The number and location of injection sites should be based on the severity of blepharospasm, and previous dose and response to onabotulinumtoxinA (Botox) injections. Subsequent dosing should be tailored to the individual patient, based on response, up to a maximum dose of 35 Units per eye [see Clinical Studies 14.4]. XEOMIN dosing has not been established in patients with blepharospasm who have not been previously treated with onabotulinumtoxinA (Botox).

The frequency of XEOMIN repeat treatments should be determined by clinical response but should generally be no more frequent than every 12 weeks [see Clinical Studies (14.4)].

Glabellar Lines

The total recommended XEOMIN dose is 20 Units per treatment session divided into five equal intramuscular injections of 4 Units each. The five injection sites are: two injections in each corrugator muscle and one injection in the procerus muscle.

Retreatment with XEOMIN should be administered no more frequently than every three months.

Figure 3: Injection Sites for Glabellar Lines

Figure 3

Special Populations

The safety and effectiveness of XEOMIN in the treatment of chronic sialorrhea, upper limb spasticity, cervical dystonia, blepharospasm, and glabellar lines in patients below 18 years of age have not been assessed [see Warnings and Precautions (5.1)].

Preparation and Reconstitution Technique

Prior to injection, reconstitute each vial of XEOMIN with sterile, preservative-free 0.9% Sodium Chloride Injection, USP [see Dosage Form and Strengths (3)]. A 20-27 gauge short bevel needle is recommended for reconstitution. Draw up an appropriate amount of preservative-free 0.9% Sodium Chloride Injection, USP into a syringe (see Table 3 and [Dosage Form and Strengths (3)]). Clean the exposed portion of the rubber stopper of the vial with alcohol (70%) prior to insertion of the needle. After vertical insertion of the needle through the rubber stopper, the vacuum will draw the saline into the vial. Gently inject any remaining saline into the vial to avoid foam formation. If the vacuum does not pull the saline into the vial, then XEOMIN must be discarded. Remove the syringe from the vial and mix XEOMIN with the saline by carefully swirling and inverting/flipping the vial – do not shake vigorously. Reconstituted XEOMIN is a clear, colorless solution free of particulate matter. XEOMIN should not be used if the reconstituted solution has a cloudy appearance or contains floccular or particulate matter.

After reconstitution, XEOMIN should be used for only one injection session and for only one patient. Reconstituted XEOMIN solution should be administered within 24 hours after dilution. During this time period, unused reconstituted XEOMIN may be stored in the original container in a refrigerator 2°C -8°C (36°F -46°F) for up to 24 hours until time of use. XEOMIN vials are for single-dose only. Discard any unused portion.

Diluent volumes for reconstitution of XEOMIN are indicated in Table 3.

Table 3: Diluent Volumes for Reconstitution of XEOMIN
Volume of Preservative-free 0.9% Sodium Chloride Injection, USP 50 Unit Vial:
Resulting dose in Units per 0.1 mL
100 Unit Vial:
Resulting dose in Units per 0.1 mL
200 Unit Vial:
Resulting dose in Units per 0.1 mL
0.25 mL 20 Units - -
0.5 mL 10 Units 20 Units 40 Units
1 mL 5 Units 10 Units 20 Units
1.25 mL 4 Units 8 Units 16 Units
2 mL 2.5 Units 5 Units 10 Units
2.5 mL 2 Units 4 Units 8 Units
4 mL 1.25 Units 2.5 Units 5 Units
5 mL 1 Unit 2 Units 4 Units


Reconstituted XEOMIN is intended for intramuscular or intra-salivary gland injection only.

If proposed injection sites are marked with a pen, the product must not be injected through the pen marks; otherwise a permanent tattooing effect may occur.

For intramuscular injections, the number of injection sites is dependent upon the size of the muscle to be treated and the volume of reconstituted XEOMIN injected.

XEOMIN should be injected carefully when injected at sites close to sensitive structures, such as the carotid artery, lung apices, and esophagus. Before administering XEOMIN, the physician should be familiar with the patient's anatomy and any anatomic alterations, e.g., due to prior surgical procedures.

Chronic Sialorrhea

A suitable sterile needle (e.g., 27-30 gauge (0.30-0.40 mm diameter), 12.5 mm length) should be used for intra-salivary gland administration for the treatment of chronic sialorrhea.

The salivary glands can be located using ultrasound imaging or surface anatomical landmarks [see Dosage and Administration (2.2)].

Upper Limb Spasticity and Cervical Dystonia

A suitable sterile needle (e.g., 26-gauge (0.45 mm diameter), 37 mm length for superficial muscles; or 22-gauge (0.70 mm diameter), 75 mm length for injections into deeper muscles) should be used in the intramuscular administration in the treatment of upper limb spasticity and cervical dystonia.

Localization of the involved muscles with electromyographic guidance or nerve stimulation techniques may be useful.


A suitable sterile needle (e.g., 30-gauge (0.40 mm diameter), 12.5 mm length) should be used in the intramuscular administration in the treatment of blepharospasm.

Glabellar Lines

A suitable sterile needle (e.g., 30-33 gauge (0.3-0.2 mm diameter), 13 mm length) should be used in the intramuscular administration in the treatment of glabellar lines.

Monitoring to Assess Effectiveness

The median first onset of XEOMIN effect occurs within seven days after injection. The typical duration of effect of each treatment is up to 3 months; however, the effect may last significantly longer, or shorter, in individual patients.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Related questions